Scholarlink

Purpose <p>To describe the outcome of cancer patients who present bloodstream infections (BSIs) by Gram-negative bacteria (GNB) and to analyze the impact of carbapenem resistance.</p> Methods <p>A retrospective study from 2021 to 2023 at a tertiary care oncologic center in Mexico. The study describes demographic, clinical, and microbiological characteristics in oncological patients with GNB-BSI.</p> Results <p>During the study period, 1348 episodes of bacteremia were included. There were 703 women (52.1%), with a mean age of 50.5 ± 16.3&#xa0;years. Five hundred thirty-six (39.7%) events were reported in patients with hematological malignancies (HM) and 814 (60.3%) in patients with solid tumors, having differences between both groups in age, gender, neutropenia, and type of BSI. Polymicrobial bacteremia was documented in 111 patients; 1468 GNB were identified. Nine hundred forty-five were classified as susceptible (64.4%), 417 (28.4%) were 3rd generation cephalosporins-resistant (C3R), and 106 (7.2%) were carbapenem-resistant (CR). CR episodes were most frequent in patients with HM, with severe neutropenia, and with &gt; 2 previous episodes of BSI. Mortality at 30&#xa0;days for the whole group was 21.1% and 37.5% for patients with CR strains. Multivariate analysis for 30-day mortality revealed that age &gt; 60&#xa0;years, severe neutropenia, bloodstream infection (BSI) other than catheter-related, polymicrobial BSI, ICU admission, CR strains, and inappropriate antimicrobial treatment were identified as risk factors.</p> Conclusions <p>Oncology patients, particularly those with HM, are a high-risk group for CR-GNB. These patients have a high mortality. Appropriate antimicrobial treatment is crucial for reducing mortality.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical outcomes in patients with cancer and Gram-negative bloodstream infection: impact of carbapenem resistance

  • 期刊论文

  • 发表日期：

    2025年7月16日

查看全文
  • Patricia Volkow-Fernández,
  • Saraí Pineda-Benitez,
  • Pamela Alatorre-Fernández,
  • Beda Islas-Muñoz,
  • Consuelo Velázquez-Acosta,
  • Patricia Cornejo-Juárez

摘要

Purpose

To describe the outcome of cancer patients who present bloodstream infections (BSIs) by Gram-negative bacteria (GNB) and to analyze the impact of carbapenem resistance.

Methods

A retrospective study from 2021 to 2023 at a tertiary care oncologic center in Mexico. The study describes demographic, clinical, and microbiological characteristics in oncological patients with GNB-BSI.

Results

During the study period, 1348 episodes of bacteremia were included. There were 703 women (52.1%), with a mean age of 50.5 ± 16.3 years. Five hundred thirty-six (39.7%) events were reported in patients with hematological malignancies (HM) and 814 (60.3%) in patients with solid tumors, having differences between both groups in age, gender, neutropenia, and type of BSI. Polymicrobial bacteremia was documented in 111 patients; 1468 GNB were identified. Nine hundred forty-five were classified as susceptible (64.4%), 417 (28.4%) were 3rd generation cephalosporins-resistant (C3R), and 106 (7.2%) were carbapenem-resistant (CR). CR episodes were most frequent in patients with HM, with severe neutropenia, and with > 2 previous episodes of BSI. Mortality at 30 days for the whole group was 21.1% and 37.5% for patients with CR strains. Multivariate analysis for 30-day mortality revealed that age > 60 years, severe neutropenia, bloodstream infection (BSI) other than catheter-related, polymicrobial BSI, ICU admission, CR strains, and inappropriate antimicrobial treatment were identified as risk factors.

Conclusions

Oncology patients, particularly those with HM, are a high-risk group for CR-GNB. These patients have a high mortality. Appropriate antimicrobial treatment is crucial for reducing mortality.